MaryAnneTagliaferriMD

PubMed

• 39 citations
  Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
  Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I. Spira, Daniel C. Cho...> ;Journal of Clinical Oncology. 2021 Jul 13
• 11 citations
  Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.
  Nina Shah, Miguel-Angel Perales, Cameron J. Turtle, Mitchell S. Cairo, Andrew J. Cowan, Hayder Saeed, Lihua E. Budde, Alan Tan, Zachary J. Lee, Kazuharu Kai, Mario Q. ...> ;Future Oncology. 2021 Jun 22
• 66 citations
  Engineering IL-2 to Give New Life to T Cell Immunotherapy
  Willem W. Overwijk, Mary Tagliaferri, Jonathan Zalevsky> ;Annual Review of Medicine. 2021 Jan 27
• 5 citations
  PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
  Robert Huddart, Arlene O. Siefker-Radtke, Arjun Vasant Balar, Mehmet Asim Bilen, Thomas Powles, Aristotelis Bamias, Daniel Castellano, Maged F. Khalil, Michiel S. van ...> ;Future Oncology. 2021 Jan 1
• 4 citations
  Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain.
  Jack E. Henningfield, Jeffrey A Gudin, Richard Rauck, Joseph Gimbel, Mary Tagliaferri, Stephen K. Doberstein, Carlo J Di Fonzo, Lin Lu, Nathaniel P. Katz, Suresh Siddh...> ;Pain Medicine. 2020 Aug 1
• 10 citations
  Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 5...
  Jeffrey Gudin, Richard Rauck, Charles Argoff, Eva Agaiby, Joseph Gimbel, Nathaniel P. Katz, Stephen K. Doberstein, Mary Tagliaferri, Margit Cecile Tagliaferri, Jeffrey...> ;Pain Medicine. 2020 Jul 1
• 133 citations
  Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
  Adi Diab, Nizar M. Tannir, Salah Eddine Bentebibel, Patrick Hwu, Vassiliki A. Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol, S...> ;Cancer Discovery. 2020 May 21
• 6 citations
  Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
  Ge Xue, Jack E. Henningfield, Suresh Siddhanti, Janet Jobes, Lin Lu, Sunny Xie, Margaret Ziola, Debra Kelsh, Bradley Vince, Carlo J Di Fonzo, Mary Tagliaferri, Jonatha...> ;Pain Medicine. 2019 Sep 25
• 16 citations
  SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain.
  John D. Markman, Jeffrey A Gudin, Richard Rauck, Charles Argoff, Michael C. Rowbotham, Eva Agaiby, Joseph Gimbel, Nathaniel P. Katz, Stephen K. Doberstein, Mary Taglia...> ;Pain. 2019 Jun 1
• 14 citations
  ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
  Debu Tripathy, Sara M. Tolaney, Andrew D. Seidman, Carey K. Anders, Nuhad K. Ibrahim, Hope S. Rugo, Chris Twelves, Véronique Diéras, Volkmar Müller, Mary Tagliaferri, ...> ;Future Oncology. 2019 May 10
• 127 citations
  A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
  Salah Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W. Hudgens, Harriet M. Kluger, Michael T. Tetzlaff, Mary Tagliaferri, Jonatha...> ;Cancer Discovery. 2019 Apr 15
• 7 citations
  Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Dr...
  Ryan K. Lanier, Jack E. Henningfield, Jeffrey A Gudin, Richard Rauck, Harrison Elder, Nathalie Erpelding, Roi Treister, Joseph Gimbel, Mary Tagliaferri, Stephen K. Dob...> ;Current Medical Research and Opinion. 2019 Apr 1
• 15 citations
  Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
  Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Seock–Ah –A Im, Alison L. Hannah, Lin Lu, Sherwin K. B. Sy, Katie Caygill, Deborah D.A. Z...> ;Clinical Cancer Research. 2018 Jul 15
• 7 citations
  Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase II...
  Javier Cortes, Hope S. Rugo, Ahmad Awada, Chris Twelves, Edith A. Perez, Seock–Ah –A Im, Patricia Gómez-Pardo, Lee S. Schwartzberg, Véronique Diéras, Denise A. Yardley...> ;Breast Cancer Research and Treatment. 2017 Nov 1
• 4 citations
  Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer
  Heinz-Josef Lenz, Philip A. Philip, Mark N. K. Saunders, Tatjana Kolevska, Kalyan Kusum Mukherjee, Leslie Samuel, Shailesh Bondarde, T. Dobbs, Mary Tagliaferri, Ute Ho...> ;Cancer Chemotherapy and Pharmacology. 2017 Oct 17
• 7 citations
  Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
  Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Seock-Ah Im, Patricia Gómez-Pardo, Lee S Schwartzberg, Veronique Diéras, Denise A Yardley, David...> ;Breast Cancer Research and Treatment. 2017 Sep 1
• 32 citations
  A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic ...
  Lee S. Schwartzberg, Francis P. Arena, Bryan J. Bienvenu, Edward H. Kaplan, Luis H. Camacho, Luis T. Campos, J. Paul Waymack, Mary Tagliaferri, Michael M. Chen, Dapeng Li> ;Journal of Cancer. 2017 Jul 3
• 11 citations
  Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: R...
  Chris Twelves, Javier Cortes, Joyce O'Shaughnessy, Ahmad Awada, Edith A. Perez, Seock–Ah –A Im, Patricia Gómez-Pardo, Lee S. Schwartzberg, Véronique Diéras, Denise A. ...> ;European Journal of Cancer. 2017 May 1
• 9 citations
  A Selective Estrogen Receptor Beta Agonist for the Treatment of Hot Flushes: Phase 2 Clinical Trial.
  Mary Tagliaferri, Margit Cecile Tagliaferri, Jennifer M. Creasman, William D Koltun> ;Journal of Alternative and Complementary Medicine. 2016 Sep 1
• 4 citations
  Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
  Javier Cortes, Hope S. Rugo, Chris Twelves, Ahmad Awada, Edith A. Perez, Seock–Ah –A Im, Carol Zhao, Ute Hoch, Denise Tomkinson, James Buchanan, Mary Tagliaferri, Alis...> ;Springerplus. 2016 Jul 8
• 56 citations
  Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capec...
  Edith A. Perez, Ahmad Awada, Joyce O'Shaughnessy, Hope S. Rugo, Chris Twelves, Seock–Ah –A Im, Patricia Gómez-Pardo, Lee S. Schwartzberg, Véronique Diéras, Denise A. Y...> ;The Lancet. Oncology. 2015 Nov 1
• 2 citations
  Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.
  Mary Tagliaferri, Jennifer M. Creasman, K. A. Caygill, A. Olyaie, Dale C. Leitman, Isaac Cohen, Deborah Grady> ;Climacteric. 2012 Nov 22
• 33 citations
  Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS.
  Vivian Chen, Richard E. Staub, Sylvia Fong, Mary Tagliaferri, Isaac Cohen, Emma Shtivelman> ;Plos One. 2012 Feb 3
• 31 citations
  Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle.
  Vivian Chen, Richard E. Staub, Scott Baggett, Ramesh Chimmani, Mary Tagliaferri, Isaac Cohen, Emma Shtivelman> ;Plos One. 2012 Jan 17
• 21 citations
  Tissue-specific regulation of genes by estrogen receptors.
  Dale C. Leitman, Sreenivasan Paruthiyil, Chaoshen Yuan, Candice B. Herber, Moshe Olshansky, Mary Tagliaferri, Isaac Cohen, Terence P. Speed> ;Seminars in Reproductive Medicine. 2012 Jan 1
• Join now to see all

Abstracts/Posters

• A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...
  Mary Tagliaferri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019